NCT06606847View on ClinicalTrials.gov

A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Oleclumab

Oleclumab IV (intravenous infusion)

DRUG

Durvalumab

Durvalumab IV (intravenous infusion)

Trial Locations (11)

111123

Research Site, Moscow

115478

Research Site, Moscow

143423

Research Site, Moscow

197022

Research Site, Saint Petersburg

197758

Research Site, Saint Petersburg

249031

Research Site, Obninsk

420029

Research Site, Kazan'

450054

Research Site, Ufa

603126

Research Site, Nizhny Novgorod

620905

Research Site, Yekaterinburg

630108

Research Site, Novosibirsk

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY